This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.
Review of the hardback: '... a book that will become a standard on drug targeting to the brain ... a must for everybody who works in the field of brain drug delivery in academia as well as in the pharmaceutical industry.' W. Kamphorst, www.bmjbookshop.com
Review of the hardback: 'This book provides an extensive review of brain drug targeting of large molecules and will be a valuable reference to those interested in completing research in this field.' Tejal Patel, Doody's Health Sciences Book Review Journal
Review of the hardback: 'This is an excellent book to be expected from a major researcher in the field. The lucid text is illuminated by an eclectic mix of diagrams and plates that will have a broad appeal to a wide audience.' A. Davenport, British Journal of Neurosurgery
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Paperback. Etat : new. Paperback. The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists to reexamine the use of drugs in treating disorders of the central nervous system. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9780521154468
Quantité disponible : 1 disponible(s)
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9780521154468
Quantité disponible : Plus de 20 disponibles
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. reissue edition. 353 pages. 9.75x7.00x0.75 inches. In Stock. This item is printed on demand. N° de réf. du vendeur __0521154464
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9780521154468_new
Quantité disponible : Plus de 20 disponibles
Vendeur : Chiron Media, Wallingford, Royaume-Uni
PF. Etat : New. N° de réf. du vendeur 6666-IUK-9780521154468
Quantité disponible : 10 disponible(s)
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting. Num Pages: 376 pages, black & white illustrations. BIC Classification: MJN; MMGW. Category: (P) Professional & Vocational. Dimension: 244 x 170 x 20. Weight in Grams: 600. . 2010. Reissue. paperback. . . . . N° de réf. du vendeur V9780521154468
Quantité disponible : Plus de 20 disponibles
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. 376. N° de réf. du vendeur 26615854
Quantité disponible : 4 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. 376 67:B&W 6.69 x 9.61 in or 244 x 170 mm (Pinched Crown) Perfect Bound on White w/Gloss Lam. N° de réf. du vendeur 8313457
Quantité disponible : 4 disponible(s)
Vendeur : Kennys Bookstore, Olney, MD, Etats-Unis
Etat : New. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting. Num Pages: 376 pages, black & white illustrations. BIC Classification: MJN; MMGW. Category: (P) Professional & Vocational. Dimension: 244 x 170 x 20. Weight in Grams: 600. . 2010. Reissue. paperback. . . . . Books ship from the US and Ireland. N° de réf. du vendeur V9780521154468
Quantité disponible : Plus de 20 disponibles
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. 376. N° de réf. du vendeur 18615844
Quantité disponible : 4 disponible(s)